Denali Therapeutics
DNLI
210 hedge funds and large institutions have $6.32B invested in Denali Therapeutics in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 81 increasing their positions, 59 reducing their positions, and 41 closing their positions.
290% more call options, than puts
Call options by funds: $30M | Put options by funds: $7.7M
38% more capital invested
Capital invested by funds: $4.6B → $6.32B (+$1.73B)
37% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 59
0.02% more ownership
Funds ownership: 66.53% → 66.56% (+0.02%)
4% less funds holding
Funds holding: 218 → 210 (-8)
17% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 41
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$133M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$33.8M |
| 3 |
BlackRock
New York
|
+$29.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$22.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$114M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$71.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32.3M |
| 4 |
Two Sigma Investments
New York
|
-$17.2M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$16.3M |
DNLI Hedge Fund Activity: Q2 2021 in Review
210 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2021, worth a combined $6.32B — up 38% from $4.6B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of DNLI and 34 opened new positions — a net loss of 7 holders — while 59 trimmed existing stakes and 81 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $133M. The largest seller was Crestline Management, cutting an estimated $114M.
- 210 institutional investors held Denali Therapeutics (DNLI) as of Q2 2021, down from 218 in Q1 2021.
- Funds reported $6.32B of Denali Therapeutics stock for Q2 2021, up 38% quarter-over-quarter.
- 34 funds opened new Denali Therapeutics positions in Q2 2021 and 41 closed out, a net change of -7 holders.
- The largest Denali Therapeutics buyer in Q2 2021 was Baillie Gifford & Co, an estimated $133M added.
- The largest Denali Therapeutics seller in Q2 2021 was Crestline Management, an estimated $114M sold.
Based on aggregated 13F filings for Q2 2021.